新辅助化疗对乳腺癌患者TOPOⅡα、P53、PS2表达的影响

Impact of neoadjuvant chemotherapy on TOPOⅡα,P53 and PS2 expressions in patients with breast cancer

目的探讨新辅助化疗对乳腺癌患者拓扑异构酶-α(TOPOⅡα)、肿瘤抑制蛋白P53(P53)、雌激素调节蛋白(PS2)表达的影响。方法选取2016年2月至2017年12月该院收治的90例乳腺癌患者,随机分为研究组和对照组,各45例。对照组患者进行常规手术操作,研究组患者采用新辅助化疗,比较两组患者治疗后的TOPOⅡα、P53、PS2表达情况和治疗效果。结果两组乳腺癌患者治疗前P53、PS2、TOPOⅡα阳性表达情况差异无统计学意义(P>0.05),研究组患者经新辅助化疗后P53、PS2、TOPOⅡα阳性表达例数明显减少,且较对照组患者更少(P<0.05)。治疗后两组患者乳腺癌病情均有所改善,研究组客观缓解率和病情控制率显著高于对照组(P<0.05)。结论新辅助化疗使乳腺癌患者P53、PS2和TOPOⅡα阳性表达例数明显减少,对于乳腺癌患者治疗效果理想,值得临床推广应用。

Objective To investigate the effect of neoadjuvant chemotherapy on the expression of TOPOⅡα,P53 and PS2 protein in the patients with breast cancer.Methods Ninety patients with breast cancer admitted to this hospital from February 2016 to December 2017 were selected and randomly divided into the study group and control group,45 cases in each group.The control group conducted the routine operation and the study group adopted the neoadjuvant chemotherapy.The expressions of TOPOⅡα,P53 and PS2 and the therapeutic effects were compared between the two groups.Results There was no statistically significant difference in the positive expression of P53,PS2 and TOPOⅡαbefore treatment between the two groups(P >0.05).The cases of P53,PS2 and TOPOⅡαpositive expression in the study group were significantly reduced after neoadjuvant chemotherapy,moreover less than that in the control group(P<0.05).After treatment,the condition of breast cancer in both groups was improved.The objective remission rate and disease control rate in the study group were significantly higher than those in the control group(P<0.05).Conclusion The neoadjuvant chemotherapy can significantly reduce the cases of P53,PS2 and TOPOⅡαpositive expression in the patients with breast cancer,has the ideal therapeutic effect and is worthy of clinical promotion and application.